Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Company Drug PIC

GSK’s Shingrix Wins Japan Approval for Prefilled Syringe Presentation – Recombinant Zoster Vaccine Gains Administration Flexibility

Fineline Cube Sep 11, 2026
Company Drug PIC

Hengrui’s Hetrombopag Wins China Approval for CTIT and Pediatric ITP – Oral TPO‑RA Expands Across Thrombocytopenia Indications

Fineline Cube Sep 11, 2026
Company Drug PIC

Roche’s Enspryng Granted FDA Priority Review for MOGAD – First IL‑6 Inhibitor Poised to Expand Beyond NMOSD

Fineline Cube Sep 11, 2026
Company Deals PIC

Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products

Fineline Cube Sep 11, 2026
Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Fineline Cube Sep 11, 2026
Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Fineline Cube Sep 11, 2026
Company Medical Device

Thermo Fisher’s Oncomine Dx Target Test Gets FDA Green Light as Companion Diagnostic for Servier’s Voranigo

Fineline Cube Oct 22, 2024

US pharmaceutical and biotechnology company Thermo Fisher Scientific (NYSE: TMO) has received marketing approval from...

Company Deals

GSK and Cambridge University Forge £50 Million Partnership to Tackle Immune Diseases

Fineline Cube Oct 22, 2024

UK pharmaceutical giant GSK plc (LON: GSK, NYSE: GSK) has unveiled a significant five-year partnership...

Company Drug

AstraZeneca’s Saphnelo Approved for Use in Guangdong Under ‘Hong Kong-Macau Drug Access’ Policy

Fineline Cube Oct 22, 2024

AstraZeneca (AZ, NASDAQ: AZN), a leading UK pharmaceutical company, has announced that its drug Saphnelo...

Company Deals

InventisBio Acquires Immuno-Oncology Assets from Lyvgen Biopharma in RMB1.5 Million Deal

Fineline Cube Oct 22, 2024

InventisBio (Shanghai) Co., Ltd (SHA: 688382), a Chinese biotechnology company, has announced a transfer agreement...

Company Drug

BeiGene’s Tevimbra Receives CHMP Recommendation for Expanded Use in G/GEJ and ESCC Cancers in EU

Fineline Cube Oct 22, 2024

BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a leading China-based biotechnology company, has received...

Company Drug

Olymvax Bio Receives NMPA Approval for Clinical Study of Trivalent Influenza Vaccine

Fineline Cube Oct 22, 2024

Olymvax Biopharmaceuticals Inc. (SHA: 688319), a leading vaccine specialist headquartered in Chengdu, has announced that...

Drug Medical Device Policy / Regulatory

Guangzhou Releases First Batch of Innovative Drugs and Medical Devices List, Featuring Local Companies

Fineline Cube Oct 22, 2024

The Guangzhou Municipal Industry and Information Technology Bureau has unveiled the first batch of innovative...

Company Drug

Sino Biopharmaceutical’s Anlotinib Receives Ninth Indication Approval from China’s CDE for Soft-Tissue Sarcoma

Fineline Cube Oct 22, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a leading pharmaceutical company in China, has announced that it...

Company

GenScript Dissolves Merger with CAR-T Specialist Legend Biotech, Reclassifies as Associated Company

Fineline Cube Oct 22, 2024

GenScript Biotech Corporation (HKG: 1548), a comprehensive life science research and application service and product...

Policy / Regulatory

China’s NMPA Greenlights Pilot Plan for Phased Manufacturing of Biological Products

Fineline Cube Oct 22, 2024

The National Medical Products Administration (NMPA) has given its stamp of approval to the “Pilot...

Company Deals

Otsuka Holdings Weighs Sale of Stake in Medical Device Maker MicroPort Scientific

Fineline Cube Oct 22, 2024

Otsuka Holdings Co., a Japanese pharmaceutical and healthcare company, is reportedly considering the sale of...

Company Deals Medical Device

Dongcheng Pharma Moves to Enhance Portfolio with Acquisition of Rongcheng Medical’s GSA Injection

Fineline Cube Oct 22, 2024

China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd. (SHE: 002675) has announced its intention to acquire...

Company Drug

Johnson & Johnson’s Akeega Approved in China as First Dual Action Tablet for mCRPC

Fineline Cube Oct 21, 2024

Johnson & Johnson (J&J, NYSE: JNJ), a leading US pharmaceutical company, has announced that China’s...

Company Drug

Everest Medicines’ Nefecon Approved in Taiwan for Primary IgAN Treatment

Fineline Cube Oct 21, 2024

Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced that it has received market...

Company Drug

BeiGene’s Tevimbra Approved in China for NSCLC Patients as Neoadjuvant and Adjuvant Therapy

Fineline Cube Oct 21, 2024

BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a leading China-based biotechnology company, has announced...

Policy / Regulatory

Tianjin Municipality Unveils Plan to Boost Synthetic Biology and Biomanufacturing Innovation

Fineline Cube Oct 21, 2024

The People’s Government of Tianjin Municipality has unveiled two significant implementation plans to bolster the...

Company Drug

Novo Nordisk’s Alhemo Receives CHMP Recommendation for Haemophilia Prophylaxis in Europe

Fineline Cube Oct 21, 2024

Novo Nordisk (NYSE: NVO), a Danish pharmaceutical company, has been notified that the Committee for...

Company Deals

Stem-Cell Startup Xellsmart Secures Over RMB 100 Million in Series B1 Financing for Neurological Therapies

Fineline Cube Oct 21, 2024

Xellsmart, a stem-cell startup headquartered in Suzhou, has reportedly secured over RMB 100 million (USD...

Company Drug

Novartis’s Kisqali Receives Positive CHMP Opinion for Early Breast Cancer Treatment in the EU

Fineline Cube Oct 21, 2024

Novartis (NYSE: NVS), the Swiss pharmaceutical giant, has announced that the Committee for Medicinal Products...

Company Drug

Kanghong Pharmaceutical’s NASH Drug KH629 Approved for Clinical Trials in China

Fineline Cube Oct 21, 2024

Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773), a Chinese pharmaceutical company, has announced that...

Posts pagination

1 … 334 335 336 … 719

Recent updates

  • Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption
  • BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis
  • Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China
  • China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories
  • Ocumension’s OT‑301 NDA Accepted by China’s CDE – Dual‑Mechanism Glaucoma Therapy Advances Toward Approval in Open‑Angle Glaucoma and Ocular Hypertension
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Company Drug

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

Policy / Regulatory

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.